http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2533887-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0973b70303a6689b2d3eca1118129321 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2004-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b27a5dea213fcdcd0916aa1a5a4e43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa2127c8e256ce0e8a0bdf062c7e9412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_513eea3bffcf581ba7ed90728ebd7926 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_659c112e619a0332126d7598c958e97e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb9c64305b634d6ee0aa814f5ae5ff32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5008f45bb283b4e4ae28398ffafa42f |
| publicationDate | 2005-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2533887-A1 |
| titleOfInvention | Injectable, oral, or topical sustained release pharmaceutical formulations |
| abstract | Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection, by oral administration or by topical administration. The injectable formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon injection of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 24 hours. The oral formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 2 hours following oral administration. The topical formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 2 hours following topical administration. |
| priorityDate | 2003-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1261.